Cardiovascular Diabetology

Article	Citations
Empagliflozin-induced lipidome remodeling in type 2 diabetes: mechanistic insights and translational perspectives	532
Pseudohypoxia caused by germline genetic alterations in the VHL gene is associated with increased diabetes and cardiovascular risk: a UK biobank study	430
Combined associations of visceral adipose tissue and adherence to a Mediterranean lifestyle with T2D and diabetic microvascular complications among individuals with prediabetes	352
Correction to: Mortality and cardiovascular events in diabetes mellitus patients at dialysis initiation treated with glucagon-like peptide-1 receptor agonists	350
Correction: Cardiometabolic risk stratification in pediatric obesity: evaluating the clinical utility of fasting insulin and BMI-SDS	324
Correction: Association between triglyceride–glucose index and mortality in critically ill patients with atrial fibrillation: a retrospective cohort study	322
Risk score for lower-limb amputation and its ability to predict major kidney and cardiovascular events in people with type 1 diabetes	251
Inpatient safety, effectiveness of SGLT2 inhibitors and GLP-1 RAs in type 2 diabetes: ENDOCARE, a pragmatic prospective cohort study	233
Impact of T2DM on right ventricular systolic dysfunction and interventricular interactions in patients with essential hypertension: evaluation using CMR tissue tracking	217
Impaired lymphangiogenesis in pericoronary adipose tissue correlates with diabetes-aggravated coronary atherosclerosis	208
Sex‑specific cardiovascular risk in estrogen‑treated androgen‑deprived males: metabolic characterization of glucose, adipose, and lipid pathways	208
Fenofibrate to prevent amputation and reduce vascular complications in patients with diabetes: FENO-PREVENT	207
Healthy longevity-associated protein improves cardiac function in murine models of cardiomyopathy with preserved ejection fraction	197
CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes	191
The predictive value of atherogenic index of plasma and clonal hematopoiesis of indeterminate potential among patients with STEMI—from a prospective cohort study	182
Sirtuins and regulatory miRNAs as epigenetic determinants of empagliflozin-mediated recovery after acute myocardial infarction	182
Large-scale multi-omics enhance risk prediction for type 2 diabetes	179
Association between triglyceride–glucose index and mortality in critically ill patients with atrial fibrillation: a retrospective cohort study	172
The interplay of inflammation, exosomes and Ca2+ dynamics in diabetic cardiomyopathy	166
Elevated urine albumin-to-creatinine ratio increases the risk of new-onset heart failure in patients with type 2 diabetes	164
High triglyceride-glucose index and stress hyperglycemia ratio as predictors of adverse cardiac events in patients with coronary chronic total occlusion: a large-scale prospective cohort study	163
SREBP1 deficiency aggravates vascular calcification via iASPP-triggered ferroptosis of vascular smooth muscle cells	162
Data-independent LC-MS/MS analysis of ME/CFS plasma reveals a dysregulated coagulation system, endothelial dysfunction, downregulation of complement machinery	159
Longitudinal assessment of coronary plaque regression related to sodium–glucose cotransporter-2 inhibitor using coronary computed tomography angiography	154
Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness an	152

Plasma ceramides are associated with MRI-based liver fat content but not with noninvasive scores of liver fibrosis in patients with type 2 diabetes	152
Safety, pharmacokinetics and pharmacodynamics of Plozasiran in Chinese healthy volunteers	149
Combined evaluation of arterial stiffness, glycemic control and hypertension for macrovascular complications in type 2 diabetes	148
The effectiveness of sodium-glucose co-transporter 2 inhibitors on cardiorenal outcomes: an updated systematic review and meta-analysis	146
Effect of dapagliflozin on the prognosis of patients with acute myocardial infarction undergoing percutaneous coronary intervention	144
Improving 10-year cardiovascular risk prediction in patients with type 2 diabetes with metabolomics	139
BMI-based obesity classification misses children and adolescents with raised cardiometabolic risk due to increased adiposity	135
Dysregulation of hypoxia-inducible factor 1α in the sympathetic nervous system accelerates diabetic cardiomyopathy	134
The association between triglyceride glucose-body mass index and all-cause mortality in critically ill patients with atrial fibrillation: a retrospective study from MIMIC-IV database	134
Association between abdominal obesity indices and risk of cardiovascular events in Chinese populations with type 2 diabetes: a prospective cohort study	133
Proteinuria and the risk of Incident atrial fibrillation according to glycemic stages: a nationwide population-based cohort study	131
In-hospital glycemic variability and all-cause mortality among patients hospitalized for acute heart failure	131
Development and validation of a machine learning model for predicting vulnerable carotid plaques using routine blood biomarkers and derived indicators: insights into sex-related risk patterns	131
Type 2 diabetes worsens the outcome of ischemia/reperfusion in female STEMI patients and female db/db mice with HFpEF cardiometabolic phenotype	128
Comprehensive transcriptomics and metabolomics analyses reveal that hyperhomocysteinemia is a high risk factor for coronary artery disease in a chinese obese population aged 40–65: a prospective cross	128
Impact of remnant cholesterol on short-term and long-term prognosis in patients with prediabetes or diabetes undergoing coronary artery bypass grafting: a large-scale cohort study	126
Multi-modal characterisation of early-stage, subclinical cardiac deterioration in patients with type 2 diabetes	121
The triglyceride-glucose index predicts 1-year major adverse cardiovascular events in end-stage renal disease patients with coronary artery disease	120
Bone proteins are associated with cardiovascular risk according to the SCORE2-Diabetes algorithm	119
Dysregulation of long non-coding RNA gene expression pathways in monocytes of type 2 diabetes patients with cardiovascular disease	118
Association between triglyceride–glucose index trajectories and radiofrequency ablation outcomes in patients with stage 3D atrial fibrillation	117
The atherogenic index of plasma and carotid atherosclerosis in a community population: a population-based cohort study in China	117
The triglyceride-glucose index is associated with atherosclerosis in patients with symptomatic coronary artery disease, regardless of diabetes mellitus and hyperlipidaemia	115
Long-term dual-trajectories of TyG and LAP and their association with cardiometabolic multimorbidity in midlife: the CARDIA study	115
Sex differences and sex steroids influence on the presentation and severity of cardiovascular autonomic neuropathy of patients with type 1 diabetes	115
Obesity-induced mesenteric PVAT remodelling is sexually dimorphic, but not driven by ovarian hormones	114
Association between non-insulin-based insulin resistance indices and cardiovascular events in patients undergoing percutaneous coronary intervention: a retrospective study	114
Association of atherogenic index of plasma and cardiometabolic index with all-cause mortality and cardiovascular disease in NAFLD patients: NHANES 1999–2018	113
Investigating sex-specific associations of lipid traits with type 2 diabetes, glycemic traits and sex hormones using Mendelian randomization	112
Associations of combined polygenic risk score and glycemic status with atrial fibrillation, coronary artery disease and ischemic stroke	110
Epigenetic crossroads in metabolic and cardiovascular health: the role of DNA methylation in type 2 diabetes and cardiovascular diseases	109
Association between triglyceride glucose-body mass index and cardiovascular outcomes in patients undergoing percutaneous coronary intervention: a retrospective study	108
Nonlinear relationship between atherogenic index of plasma and the risk of prediabetes: a retrospective study based on Chinese adults	106
Association between the triglyceride glucose index and in-hospital and 1-year mortality in patients with chronic kidney disease and coronary artery disease in the intensive care unit	106
The association between index-year, average, and variability of the triglyceride-glucose index with health outcomes: more than a decade of follow-up in Tehran lipid and glucose study	100
Cardiovascular–kidney–metabolic syndrome: a comprehensive review of pathophysiology, epidemiology, diagnosis, and management	100
Pericoronary adipose tissue radiomics to improve risk stratification for patients with acute coronary syndrome: a multicenter retrospective cohort study	99
Ethnicity should be included as a risk factor for coronary artery calcium score	96
Atrial dysfunction: a contrast-free marker for HFpEF in obese diabetics—insights from comprehensive CMR and serum biomarker analyses	96
Correction: Higher HbA1c variability is associated with increased arterial stiffness in individuals with type 1 diabetes	96
Stratifying cardiovascular benefits from GLP-1RA: a multisource analysis of patient-level CVOT and real-world data using AI-driven methods	95
Real-world characteristics, modern antidiabetic treatment patterns, and comorbidities of patients with type 2 diabetes in central and Eastern Europe: retrospective cross-sectional and longitudinal eva	94
Epicardial adipose tissue volume is associated with impaired left ventricular strain in patients with metabolic syndrome: the mediating role of myocardial energetic efficiency	94
Effects of metabolic syndrome and its components on myocardial microcirculation in obstructive coronary artery disease patients: a CMR perfusion study	94
Association of temporal change in body mass index with sudden cardiac arrest in diabetes mellitus	93
Preeclampsia as an independent predictor of atherosclerosis progression in women with type 1 diabetes: a 5-year prospective study	93
Effects of exenatide on coronary stent’s endothelialization in subjects with type 2 diabetes: a randomized controlled trial. The Rebuild study	92
Marine n-3 fatty acid treatment for carotid plaques in patients with type 2 diabetes	92
Impacts of ketogenic diet intervention on cardiometabolic outcomes in obese, dysglycemic mice	91
Systematic comparison of triglyceride-glucose (TYG)-index with other mortality predictive models in obese patients with different mortality rates	91

Destabilization of cardiac myosin acetylation and sequestration with type 2 diabetes mellitus	91
Head-to-head comparison of fasting-insulin-based versus non-insulin-based insulin resistance surrogates for predicting all-cause and cardiovascular mortality in hypertensive adults across the glycemic	90
The effect of empagliflozin on inflammation in patients with overweight or obesity and risk of heart failure: a substudy from the Empire Prevent Metabolic trial	90
MetSCORE: a molecular metric to evaluate the risk of metabolic syndrome based on serum NMR metabolomics	89
The association between the triglyceride–glucose index and vulnerable plaques in patients with type 2 diabetes mellitus: insights from coronary computed tomography angiography	88
Deficiency of neutral cholesterol ester hydrolase 1 (NCEH1) impairs endothelial function in diet-induced diabetic mice	87
Targeted proteomics of extreme vascular phenotypes in type 1 diabetes: the ESCAPER study	86
Modulation of PKCα/ETS1 by klotho restores CYB5R4-dependent mitochondrial function in proximal tubular epithelial cells to attenuate the progression of diabetic kidney disease	86
Multi-trajectories of triglyceride-glucose index and lifestyle with Cardiovascular Disease: a cohort study	85
Risk factors for cardiovascular disease in patients with metabolic-associated fatty liver disease: a machine learning approach	83
Clinical potential of inclisiran for patients with a high risk of atherosclerotic cardiovascular disease	83
Clinical perspectives of new insights and tools to minimize the hypoglycaemia burden connected with type 2 diabetes pharmacotherapy	83
Independent effects of the triglyceride-glucose index on all-cause mortality in critically ill patients with coronary heart disease: analysis of the MIMIC-III database	83
Dapagliflozin treatment is associated with a reduction of epicardial adipose tissue thickness and epicardial glucose uptake in human type 2 diabetes	81
Biomarkers of glucose-insulin homeostasis and incident type 2 diabetes and cardiovascular disease: results from the Vitamin D and Omega-3 trial	80
Plasma metabolite profile of legume consumption and future risk of type 2 diabetes and cardiovascular disease	80
Advances in cardiac organoid research: implications for cardiovascular disease treatment	80
Yearly attained adherence to Mediterranean diet and incidence of diabetes in a large randomized trial	78
Dual-trajectory of TyG levels and lifestyle scores and their associations with ischemic stroke in a non-diabetic population: a cohort study	78
Associations of six insulin resistance-related indices with the risk and progression of cardio-renal-metabolic multimorbidity: evidence from the UK biobank	77
Sex differences in myocardial flow reserve among individuals with type 2 diabetes: insights from the DiaHeart study	76
Plasma lipidic fingerprint associated with type 2 diabetes in patients with coronary heart disease: CORDIOPREV study	75
Stress hyperglycemia ratio and in-hospital prognosis in non-surgical patients with heart failure and type 2 diabetes	75
Association between combined atherogenic and frailty index and cardiovascular events: evidence from the CHARLS cohort	74
Metabolic rewiring through succinate–GPR91 signaling: a fresh perspective on HFpEF energetics	74
Triglyceride-glucose index is associated with a higher risk of stroke in a hypertensive population	73
Predicting major adverse cardiac events in diabetes and chronic kidney disease: a machine learning study from the Silesia Diabetes-Heart Project	72
Tirzepatide, a dual GIP/GLP1-receptor co-agonist preserves cardiac function and improves survival in angiotensin II-induced heart failure model in mice: comparison to liraglutide	72
Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms	72
Association between C-reactive protein-triglyceride glucose index and stroke risk in different glycemic status: insights from the China Health and Retirement Longitudinal Study (CHARLS)	71
The synergistic effect of the triglyceride-glucose index and a body shape index on cardiovascular mortality: the construction of a novel cardiovascular risk marker	71
The association between triglyceride-glucose index and its combination with obesity indicators and cardiovascular disease: NHANES 2003–2018	71
The association of triglyceride-glucose and triglyceride-glucose related indices with the risk of heart disease in a national cohort study	70
Combined effect of skeletal muscle mass loss and elevated insulin resistance on heart failure risk in older adults: a community-based longitudinal cohort study	70
Rapid kidney function decline and increased risk of heart failure in patients with type 2 diabetes: findings from the ACCORD cohort	70
The cardiovascular and renal effects of glucagon-like peptide 1 receptor agonists in patients with advanced diabetic kidney disease	70
Phenotypic heterogeneity of type 2 diabetes and risks of complications with a tree-like representation	69
Monocytes perturbation implicated in the association of stress hyperglycemia with postoperative poor prognosis in non-diabetic patients with Stanford type-A acute aortic dissection	69
Diabetes does not increase in-hospital or short-term mortality in patients undergoing surgical repair for type A aortic dissection: insight from the national readmission database	69
Estimated potassium intake and major adverse cardiovascular events in individuals with type 2 diabetes: a prospective cohort study with trans-ethnic validation	69
Development and validation of a model to predict cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in patients with type 2 diabetes mellitus and established atherosclerotic card	68
Relationship between the circulating N-terminal pro B-type natriuretic peptide and the risk of carotid artery plaque in different glucose metabolic states in patients with coronary heart disease: a CS	68
Clonal hematopoiesis of indeterminate potential and type 2 diabetes mellitus among patients with STEMI: from a prospective cohort study combing bidirectional Mendelian randomization	67
Inflammation-related 5-hydroxymethylation signatures as markers for clinical presentations of coronary artery disease	67
Distinct compositional alterations in plasma lipoproteins in type 2 diabetes: a cross-sectional study of healthy individuals and diabetics with and without cardiovascular comorbidities	67
Glycemic control and clinical outcomes in diabetic patients with heart failure and reduced ejection fraction: insight from ventricular remodeling using cardiac MRI	67
Longitudinal economic burden of incident complications among metabolic syndrome populations	67
Cardiorenal protection with dapagliflozin in patients with type 2 diabetes mellitus and chronic coronary syndrome undergoing percutaneous coronary intervention: a registry cross-sectional study	67
Causal associations between insulin and Lp(a) levels in Caucasian population: a Mendelian randomization study	66
The predictive value of lesion-specific pericoronary fat attenuation index for major adverse cardiovascular events in patients with type 2 diabetes	66
Association of the triglyceride glucose index with all-cause and cardiovascular mortality in a general population of Iranian adults	66
Role of continuous glucose monitoring in diabetic patients at high cardiovascular risk: an expert-based multidisciplinary Delphi consensus	66
Assessment of left atrioventricular coupling and left atrial function impairment in diabetes with and without hypertension using CMR feature tracking	65
Prognostic stratification with composite insulin resistance–inflammation biomarkers in patients with chronic kidney disease and coronary artery disease across glycemic statuses	65
Sodium-glucose cotransporter 2 inhibitors, inflammation, and heart failure: a two-sample Mendelian randomization study	65
SGLT2 inhibition, circulating metabolites, and atrial fibrillation: a Mendelian randomization study	65
Triglyceride glucose-weight-adjusted waist index as a cardiovascular mortality predictor: incremental value beyond the establishment of TyG-related indices	65
CVOT Summit Report 2025: advances along the cardiovascular–kidney–metabolic disease continuum	65
Joint assessment of abdominal obesity and non-traditional lipid parameters for primary prevention of cardiometabolic multimorbidity: insights from the China health and retirement longitudinal study 20	64
Prognostic impacts of diabetes status and lipoprotein(a) levels in patients with ST-segment elevation myocardial infarction: a prospective cohort study	64
GLP-1 receptor agonists-SGLT-2 inhibitors combination therapy and cardiovascular events after acute myocardial infarction: an observational study in patients with type 2 diabetes	63
The association between triglyceride glucose-waist height ratio index and cardiometabolic multimorbidity among Chinese middle-aged and older adults: a national prospective cohort study	63
Novel lipid indicators and the risk of type 2 diabetes mellitus among Chinese hypertensive patients: findings from the Guangzhou Heart Study	62
Non-coding RNA-mediated endothelial-to-mesenchymal transition in human diabetic cardiomyopathy, potential regulation by DNA methylation	62
Comparative effects of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors on heart failure with preserved ejection fraction in diabetic patients: a meta-analysis	62
Longitudinal inflammatory-metabolic-adiposity burden and incident heart failure across cardiovascular-kidney-metabolic stages: a prospective cohort study	62
Joint association of the triglyceride–glucose index and stress hyperglycemia ratio with incidence and mortality risks of new-onset atrial fibrillation during sepsis: a retrospective cohort study	62
Endothelial microRNAs in INOCA patients with diabetes mellitus	61
Left ventricular ejection fraction reserve and its association with myocardial perfusion, coronary calcification, and strain in type 2 diabetes without overt cardiovascular disease	61
The additional impact of metabolic syndrome on left ventricular deformation and myocardial energetic efficiency impairment in ischemia with nonobstructive coronary arteries patients	61
Anti-obesity therapy for cardiovascular disease prevention: potential expected roles of glucagon-like peptide-1 receptor agonists	61
Lack of impact of ipragliflozin on endothelial function in patients with type 2 diabetes: sub-analysis of the PROTECT study	61
Nanocarrier SIroliMus-coated balloon-based percutaneous coronary intervention (PCI) versus drug-eluting stent (DES)-onLy PCI in patients with diabetes mellitus	61
One-year outcomes of polymer-free amphilimus-eluting stents versus durable polymer zotarolimus-eluting stents in patients with diabetes mellitus: a meta-analysis	61
Relationships between ankle blood pressure indices and major adverse cardiovascular events in people with and without type 2 diabetes	61
Effects of diabetes mellitus on left ventricular function and deformation in patients with restrictive cardiomyopathies: a 3.0T CMR feature tracking study	61
Metabotype identification via fasting and postprandial metabolomics and its association with type 2 diabetes incidence	61
Body-weight variability and risk of cardiovascular outcomes in patients with type 1 diabetes: a retrospective observational analysis of data from the DCCT/EDIC population	60
The dual GLP-1 and GIP receptor agonist tirzapetide provides an unintended interaction with the β-adrenoceptors and plays a role in glucose metabolism in hyperglycemic or senescent cardiac cells	60
Patients with persistent atrial fibrillation and metabolic comorbidities have an altered inflammatory state of atrial epicardial adipose tissue, which is linked to CT-attenuation	60

Comprehensive CMR evaluation including 4D flow-derived E/A vorticity ratio in overweight adults with and without type 2 diabetes mellitus	60
Predicting gestational diabetes mellitus risk at 11–13 weeks’ gestation: the role of extrachromosomal circular DNA	60
Combination of GLP-1 receptor agonists and SGLT2 inhibitors in cardiometabolic disease: synergistic, additive, or non-additive effects? A narrative review	60
Endotrophin is a risk marker of complications in CANagliflozin cardioVascular Assessment Study (CANVAS): a randomized controlled trial	59
Ancestry-specific genetics of amino acids and microbiota-related metabolites reveal causal effects on cardiometabolic disease in Chinese populations	59
Association of stress hyperglycemia ratio and poor long-term prognosis in patients with myocardial infarction with non-obstructive coronary arteries	59
ApoC-III proteoforms are associated with better lipid, inflammatory, and glucose profiles independent of total apoC-III	59
Epicardial adipose tissue volume and arterial stiffness in people living with diabetes: the METAB-CV-PWV study	58
Association between the triglyceride–glucose index and severity of coronary artery disease	58
Mitochondrial network remodeling of the diabetic heart: implications to ischemia related cardiac dysfunction	58
Expanded response letter to “Hemodialysis dose and frequency should be considered in the subgroup analysis”	58
GPR30-driven fatty acid oxidation targeted by ginsenoside Rd maintains mitochondrial redox homeostasis to restore vascular barrier in diabetic retinopathy	57
Association between diabetes mellitus and primary restenosis following endovascular treatment: a comprehensive meta-analysis of randomized controlled trials	57
Neutral effects of SGLT2 inhibitors in acute coronary syndromes, peripheral arterial occlusive disease, or ischemic stroke: a meta-analysis of randomized controlled trials	56
Heparanase inhibition as a systemic approach to protect the endothelial glycocalyx and prevent microvascular complications in diabetes	56
Cumulative exposure to the estimated glucose disposal rate and incident stroke in individuals with cardiovascular–kidney–metabolic syndrome stages 0–4: 6-year longitudinal evidence from CHARLS	55
Sex-specific cardiometabolic multimorbidity, metabolic syndrome and left ventricular function in heart failure with preserved ejection fraction in the UK Biobank	55
Independent association of thigh muscle fat density with vascular events in Korean adults	55
Non-alcoholic fatty liver disease risk with GLP-1 receptor agonists and SGLT-2 inhibitors in type 2 diabetes: a nationwide nested case–control study	54
The novel triglyceride‒glucose-weighted adjusted waist index as a supplementary diagnostic tool for heart failure: evidence of improved reclassification beyond traditional TyG-related indices from a c	54
Adipsin improves diabetic hindlimb ischemia through SERPINE1 dependent angiogenesis	53
Associations of different insulin resistance-related indices with the incidence and progression trajectory of cardiometabolic multimorbidity: a prospective cohort study from UK biobank	53
Triglyceride glucose index predicts long-term mortality and major adverse cardiovascular events in patients with type 2 diabetes	53
Association of cholesterol, high-density lipoprotein and glucose (CHG) index with mortality risk in metabolic dysfunction-associated steatotic liver disease (MASLD) adults: results from two prospectiv	53
Pathways from insulin resistance to incident cardiovascular disease: a Bayesian network analysis	53
Triglyceride-glucose-related indices and risk of cardiovascular disease and mortality in individuals with cardiovascular–kidney–metabolic (CKM) syndrome stages 0–3: a prospective cohort study of 282,9	53
Epicardial adipose tissue volume and nephropathy in people living with type 2 diabetes: the Kidn-EAT study	52
The neutrophil–lymphocyte ratio as a risk factor for all-cause and cardiovascular mortality among individuals with diabetes: evidence from the NHANES 2003–2016	52
Cardiovascular risk of metabolically healthy obesity in two european populations: Prevention potential from a metabolomic study	52
Ion channel Piezo1 activation aggravates the endothelial dysfunction under a high glucose environment	52
Heart rate variability tests for diagnosing cardiovascular autonomic neuropathy in patients with type 2 diabetes mellitus in advanced stages of kidney disease	52
Glycemic control, HbA1c variability, and major cardiovascular adverse outcomes in type 2 diabetes patients with elevated cardiovascular risk: insights from the ACCORD study	51
Correction: Nut consumption is associated with a shift of the NMR lipoprotein subfraction profile to a less atherogenic pattern among older individuals at high CVD risk	51
Cardiovascular risk of gabapentin and pregabalin in patients with diabetic neuropathy	51
Correction: Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study	51
Predicting 28-day all-cause mortality in patients admitted to intensive care units with pre-existing chronic heart failure using the stress hyperglycemia ratio: a machine learning-driven retrospective	51
STIM1-mediated Treg instability in HFpEF: a new immunological target emerges?	51
Lipids and apolipoproteins affect the risk of ST-elevation and non-ST-elevation myocardial infarctions differently in type 1 diabetes: a nationwide finnish cohort study	51
Aldose reductase inhibition alleviates diabetic cardiomyopathy and is associated with a decrease in myocardial fatty acid oxidation	50
Prognostic significance of plasma SDF-1 in acute ischemic stroke patients with diabetes mellitus: the CATIS trial	50
Insulin growth factor axis and cardio-renal risk in diabetic kidney disease: an analysis from the CREDENCE trial	50
Sodium-glucose co-transporter 2 inhibitor use in patients with diabetes mellitus undergoing endovascular therapy for symptomatic peripheral artery disease	49
Associations of genetic markers of diabetes mellitus with carotid atherosclerosis: a community-based case–control study	49
Low-frequency variants in genes involved in glutamic acid metabolism and γ-glutamyl cycle and risk of coronary artery disease in type 2 diabetes	49
The impact of prior exposure to hypoglycaemia on the inflammatory response to a subsequent hypoglycaemic episode	49
Incidence of stroke, subsequent clinical outcomes and health care resource utilization in people with type 2 diabetes: a real-world database study in France: “INSIST” study	48
Cohort profile: The DIabetes and ST-segment Elevation Myocardial Infarction (DISTEMI) Study	48
Different roles of protein biomarkers predicting eGFR trajectories in people with chronic kidney disease and diabetes mellitus: a nationwide retrospective cohort study	48
Joint association of urinary albumin-to-creatinine ratio within normal range and triglyceride-glucose index with incident cardiovascular disease: a prospective cohort study	48
Management of type 2 diabetes with a treat-to-benefit approach improved long-term cardiovascular outcomes under routine care	48
Circulating PCSK9 as a prognostic biomarker of cardiovascular events in individuals with type 2 diabetes: evidence from a 16.8-year follow-up study	47
Impact of mental disorders on the risk of atrial fibrillation in patients with diabetes mellitus: a nationwide population-based study	47
The triglyceride-glucose index: a novel predictor of stroke and all-cause mortality in liver transplantation recipients	46
Relationship between TyG index and the degree of coronary artery lesions in patients with H-type hypertension	46
Measures of comorbid cardiometabolic burden and cardiovascular disease risk in people with MRI-confirmed steatotic liver disease: a prospective cohort study	46
GULP1 protects against diabetic cardiomyopathy through IKIP/NF-κB-dependent improvement of mitochondrial function	46
Sex-related differences for uric acid in the prediction of cardiovascular events in essential hypertension. A population prospective study	46
Longitudinal variability of lipoprotein(a) in youth-onset type 1 diabetes: implications for cardiovascular risk stratification	46
Daily low dose aspirin halves incident type 2 diabetes in elderly subjects with prediabetes: a five-year longitudinal cohort study in a real-word population	46
Single-cell insights: pioneering an integrated atlas of chromatin accessibility and transcriptomic landscapes in diabetic cardiomyopathy	46
Associations of insulin resistance-related indices with the risk and progression of cardiometabolic multimorbidity in individuals with metabolic dysfunction-associated steatotic liver disease: a prosp	46
Real-world cardiovascular effectiveness of sustained glucagon-like peptide 1 GLP-1 receptor agonist usage in type 2 diabetes	46
Association between atherogenic index of plasma (AIP) and all-cause and cardiovascular mortality in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): a cohort study based	45
Joint associations of anthropometric indices and C-reactive protein-triglyceride-glucose index with incident hypertension: a stratified analysis by blood pressure level from the CHARLS, 2011–2020	45
Synergistic SGLT2 and GLP-1R targeting alleviates systemic inflammation-induced and M1 monocyte-driven endothelial dysfunction in coronary artery disease	45
Hemoglobin A1c and abdominal obesity as predictors of diabetes and ASCVD in individuals with prediabetes in UK Biobank: a prospective observational study	45
Divergent mitochondrial and fibrotic signatures in atrial fibrillation: insights from organoids and GEO data	45
Association between the stress hyperglycemia ratio and severity of coronary artery disease under different glucose metabolic states	44
Association of cumulative cholesterol-HDL-glucose index with blood pressure changes and risk of new-onset hypertension in middle-aged and older adults: a cohort study	44
Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention	44
Associations between the C-reactive protein-triglyceride glucose index and the incidence and progression trajectory of cardiometabolic multimorbidity: a multi-state model study	44
The right ventricular dysfunction and ventricular interdependence in patients with T2DM and aortic regurgitation: an assessment using CMR feature tracking	44
Associations of estimated glucose disposal rate with frailty progression: results from two prospective cohorts	44
Elevated triglyceride-glucose index and risk of thymoma-associated myasthenia gravis: a prospective analysis from the UK Biobank	44
Liraglutide reduces plasma dihydroceramide levels in patients with type 2 diabetes	43
Bone marrow mesenchymal stem cell-derived extracellular vesicles alleviate diabetes-exacerbated atherosclerosis via AMPK/mTOR pathway-mediated autophagy-related macrophage polarization	43
The association between TyG index and cardiovascular mortality is modified by antidiabetic or lipid-lowering agent: a prospective cohort study	43
Extended-release metformin improves cognitive impairment in frail older women with hypertension and diabetes: preliminary results from the LEOPARDESS Study	43
Contributions of elevated CRP, hyperglycaemia, and type 2 diabetes to cardiovascular risk in the general population: observational and Mendelian randomization studies	42
Altered RBC deformability in diabetes: clinical characteristics and RBC pathophysiology	42
Correction to: Association between the triglyceride-glucose index and the risk of mortality among patients with chronic heart failure: results from a retrospective cohort study in China	42
Association of triglyceride glucose index and triglyceride glucose-body mass index with sudden cardiac arrest in the general population	42
MiRNA-132/212 encapsulated by adipose tissue-derived exosomes worsen atherosclerosis progression	42
The interplay of galectins-1, -3, and -9 in the immune-inflammatory response underlying cardiovascular and metabolic disease	42
Association between triglyceride glucose index and arterial stiffness and coronary artery calcification: a systematic review and exposure-effect meta-analysis	42
ALDH2 mediates the effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i) on improving cardiac remodeling	42
Insulin resistance quantified by estimated glucose disposal rate predicts cardiovascular disease incidence: a nationwide prospective cohort study	42
Differential associations between novel triglyceride-glucose-obesity indices and incident stroke in individuals with early-stage cardiovascular-kidney-metabolic syndrome: a longitudinal cohort study	42
Time-dependent event accumulation in a cardiovascular outcome trial of patients with type 2 diabetes and established atherosclerotic cardiovascular disease	41
Cardiomyocyte-specific NHE1 overexpression confers protection against myocardial infarction during hyperglycemia	41
Associations of cumulative exposure and dynamic trajectories of the C-reactive protein-triglyceride-glucose index with incident cardiovascular disease in middle-aged and older Chinese adults: a nation	41
Arterial collagen IV and laminin levels associate with type 2 diabetes, glycemic control, major adverse cardiac events, and mortality in coronary bypass patients	41
Lifestyle factors and their relative contributions to longitudinal progression of cardio-renal-metabolic multimorbidity: a prospective cohort study	41
Impact of left ventricular dilatation on biventricular function and deformation in diabetes mellitus with reduced ejection fraction: a CMR feature tracking study	41
Evaluative performance of TyG-ABSI versus traditional indices in relation to cardiovascular disease and mortality: evidence from the U.S. NHANES	41